ライフサイエンスコーパス: RYGB

1 RYGB increases intestinal glucose disposal and VSG delay

2 RYGB influenced 9 fecal and 3 plasma BAs in patients wit

3 RYGB is an effective strategy for midterm BP control and

4 RYGB patients were 1:1 propensity-score matched with sle

5 RYGB was characterized by accelerated absorption of gluc

6 (0.99 +/- 0.06 vs 1.04 +/- 0.06; P < 0.05), RYGB induced significantly greater increase in INR in th

7 y operations were registered, 33,029 (70.1%) RYGB and 14,072 (29.9%) SG.

8 exploratory randomized crossover design, 10 RYGB-operated patients and 10 matched controls ingested

9 Among 1087 RYGB patients, 651 (60%) had complete 10-year follow-up,

10 Among 13,900 SG, 17,258 RYGB, and 87,965 nonsurgical patients, the 5-year follow

11 n June 2012 and May 2017, we identified 4120 RYGB and 1457 SG low-risk cases defined by absence of pr

12 NASH was present in 54.5% RYGB and 51.5% SG patients (P > 0.05).

13 The matched cohort included 1111 VSG and 922 RYGB patients: 16% were younger than 40 years, 11% were

14 Participants were 957 RYGB patients enrolled in an ongoing longitudinal cohort

15 After RYGB, 24 of 26 patients had steatorrhea and urine oxalat

16 ymptoms was identified in 45/206 (22%) after RYGB.

17 % off medications) was observed in 49% after RYGB and 28% after SG (P < 0.001).

18 t the prescription drug use before and after RYGB surgery.

19 Before and after RYGB, high oxalate intake contributed to the severity of

20 in severely obese patients before and after RYGB.

21 patients reported improved well-being after RYGB surgery, but the prevalence of symptoms was high an

22 ear if longer-term outcomes are better after RYGB due to greater weight loss and/or other factors.

23 ide 1, peptide YY, and cholecystokinin after RYGB, whereas levels of ghrelin were lower after SG, com

24 a frequent postoperative complication after RYGB surgery.

25 ommonly leading to health care contact after RYGB surgery were abdominal pain (489 [34.2%]), fatigue

26 earance of ingested glucose was faster after RYGB and SG vs controls; the peak glucose appearance rat

27 ), that emulates the altered bile flow after RYGB without other manipulations of gastrointestinal ana

28 (22.8% vs 10.9%) and increased further after RYGB-that is, antidepressants (PR = 1.13; 95% CI = 1.07-

29 Readmission rates were higher after RYGB (4.3% vs 3.4%, P < 0.001).One-year post surgery, le

30 e from ingested casein was 118% higher after RYGB (P < .01), but similar between patients who had und

31 ates for all comorbidities were higher after RYGB than AGB.

32 glucose appearance rate was 64% higher after RYGB, and 23% higher after SG (both P < .05); the peak p

33 Hyperoxaluria after RYGB correlated with steatorrhea and was presumably caus

34 diet (VLCD) intervention, immediately after RYGB, and after a 6-week recovery period.

35 ional normalized ratio (INR) increased after RYGB (0.98 +/- 0.05 vs 1.14 +/- 0.11; P < 0.05) and SG (

36 red over 6 h postprandially) increased after RYGB (from 10% +/- 8% before to 15% +/- 9% after surgery

37 cidence of PHH significantly increased after RYGB but remained stable between 1 and 5 years.

38 uropsychiatric drugs further increased after RYGB.

39 intestinal glucose disposal increases after RYGB surgery.

40 eases in objectively-measured PA level after RYGB, PA level was independently associated with weight

41 While the weight-loss after RYGB was similar between hospitals, there was a great va

42 associated with long-term weight loss after RYGB were identified.

43 rove long-term weight loss maintenance after RYGB.

44 els for remission of diabetes mellitus after RYGB and AGB, age (RYGB: odds ratio [OR], 0.976; 95% CI,

45 ons were performed before and 3 months after RYGB.

46 paring prescription drug use 36 months after RYGB/index date with use 6 months before this date (base

47 e patients admitted for abdominal pain after RYGB and undergoing CT and surgical exploration were inc

48 iate logistic regression analysis, PHH after RYGB was independently associated with lower age (P = 0.

49 fy patients at risk for developing PHH after RYGB.

50 tion in the magnitude of weight regain after RYGB, highlighting the importance of patient-level facto

51 ter possibility for diabetes remission after RYGB [odds ratio, 2.16 (95% CI 1.10-4.26)], after adjust

52 ater probability of diabetes remission after RYGB and may serve as a diagnostic marker in preoperativ

53 Symptoms after RYGB surgery were reported by 1266 patients (88.6%); 966

54 ely (41%) did not report such symptoms after RYGB.

55 ase persisted at 10 years of follow-up after RYGB.

56 constipation preoperatively and 2 year after RYGB were 1.5 (0.9) and 1.8 (1.2), and for diarrhea 1.4

57 erely obese patients before and 1 year after RYGB, while patients consumed their usual diet.

58 33 participants (12%) had IBS, 2 years after RYGB 61/233 (26%) had IBS-like symptoms (p < 0.001).

59 revalence of IBS-like symptoms 2 years after RYGB and possible preoperative predictors of such sympto

60 Three years after RYGB surgery, we found large reductions in the use of tr

61 or more symptoms a median of 4.7 years after RYGB surgery.

62 e of IBS-like symptoms doubled 2 years after RYGB, and these symptoms were associated with reduced HR

63 f diabetes mellitus after RYGB and AGB, age (RYGB: odds ratio [OR], 0.976; 95% CI, 0.965-0.988 and AG

64 For remission of hypertension, age (RYGB: OR, 0.964; 95% CI, 0.957-0.972 and AGB: OR, 0.968;

65 was statistically-significantly higher among RYGB patients (4.9% vs 2.7%, P = 0.035, E-value 1.27).

66 was statistically-significantly higher among RYGB patients; however, the E-value for this difference

67 years, the use had decreased slightly among RYGB patients [PR = 0.93; 95% confidence interval (CI) =

68 ight loss (%TWL) and regain at 5 years among RYGB, SG, and nonsurgical patients, and at 10 years for

69 markedly during the initial 1-3 mo after an RYGB, whereas the BMR moderately decreased.

70 ale patients during the initial 3 y after an RYGB.

71 showed the typical pattern reported after an RYGB.

72 anges in body composition over time after an RYGB.

73 to follow-up (12.1% vs 16.5%, P < 0.001) and RYGB resulted in a higher rate of patients with total we

74 Exercise and RYGB had an additive effect on enhancing insulin sensiti

75 ur results provide evidence that obesity and RYGB have a dynamic effect on the skeletal muscle proteo

76 y was to investigate the role of obesity and RYGB on the human skeletal muscle proteome.

77 nction with similar weight loss after SG and RYGB in obese patients with T2DM.

78 nts with severe obesity who underwent SG and RYGB lost significantly more weight at 5 years than nons

79 eatic hormone secretions differ after SG and RYGB.

80 n using an IVGTT were similar between SG and RYGB.

81 oved and worsened GERD symptoms after SG and RYGB.

82 e studies on diabetes outcomes after VSG and RYGB.

83 els, high vitamin B(1) levels and IBS before RYGB were independent preoperative predictors of IBS-lik

84 , and in those with surgical symptoms before RYGB surgery (PR, 1.34; 95% CI, 1.25-1.43).

85 x, smoking, and experiencing symptoms before RYGB surgery.

86 ulation was slightly lower after than before RYGB (85% +/- 9% and 90% +/- 8%, respectively) but was s

87 heir well-being was improved after vs before RYGB surgery, while 113 (8.1%) reported reduced well-bei

88 lthough most adults who smoked 1-year before RYGB quit pre-surgery, smoking prevalence rebounded acro

89 Demographics were similar between RYGB (n = 673) and sleeve gastrectomy (n = 673) cohorts.

90 ired using the Red, Yellow, Green, and Blue (RYGB) hue and saturation scaling model.

91 Both RYGB and AGB led to statistically and clinically signifi

92 Benchmark values for both RYGB and SG at 90-days postoperatively were 5.5% Clavien

93 plasma glucose area under the curve in both RYGB and LAGB groups (-4% +/- 9% and -6% +/- 5%, respect

94 weight loss ( approximately 21%) induced by RYGB (n = 16) or LAGB (n = 9).

95 Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) account for >95% of ba

96 rt-term outcome of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in Sweden, Norway, and

97 in responses after Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG) and to ident

98 c surgery, namely, Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy.

99 term durability of Roux-en-Y Gastric Bypass (RYGB) at an accredited center.

100 After Roux-en-Y gastric bypass (RYGB) chronic abdominal pain is common, however the etio

101 rans who underwent Roux-en-Y gastric bypass (RYGB) compared with nonsurgical matches and the 4-year w

102 tiating effects to Roux-en-Y gastric bypass (RYGB) in rodent obesity models.

103 strectomy (SG) and Roux-en-Y gastric bypass (RYGB) induce substantial weight loss and improve glycemi

104 yperoxaluria after Roux-en-Y gastric bypass (RYGB) is generally attributed to fat malabsorption.

105 The effect of a Roux-en-Y gastric bypass (RYGB) on body weight has been amply documented, but few

106 ectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric patients with non-a

107 with a history of Roux-En-Y gastric bypass (RYGB) operation with a high risk of postprandial hypogly

108 rminology code for Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding (AGB) in the MarketS

109 function following Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB)

110 stable gastric band (AGB) to gastric bypass (RYGB) or sleeve gastrectomy (SG).

111 were randomized to Roux-en-Y gastric bypass (RYGB) or to hypocaloric diet (HC diet) restriction.

112 rocedures, such as Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG), are the most

113 atients undergoing Roux-en-Y gastric bypass (RYGB) surgery and a matched population-based comparison

114 improvements after Roux-en-Y gastric bypass (RYGB) surgery are not entirely clear.

115 of symptoms after Roux-en-Y gastric bypass (RYGB) surgery are sparse.

116 loss 5 years after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity in a large nationwide c

117 etes after primary Roux-en-Y gastric bypass (RYGB) surgery, in patients with and without pharmacologi

118 upregulated after Roux-en-Y gastric bypass (RYGB) surgery, which contributes to a weight-loss-indepe

119 Roux-en-Y gastric bypass (RYGB) was associated with a higher rate of insulin cessa

120 trectomy (VSG) and Roux-en-Y gastric bypass (RYGB) with respect to diabetes treatment outcomes.

121 ents who underwent Roux-en-Y gastric bypass (RYGB), cholecystectomy, partial colectomy, appendectomy,

122 , eating, obesity, Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG), oral glucose a

123 lems in women post-Roux-en-Y gastric bypass (RYGB).

124 trectomy (VSG) and Roux-en-Y gastric bypass (RYGB).

125 ment compared with Roux-en-Y gastric bypass (RYGB).

126 ia is a risk after Roux-en-Y gastric bypass (RYGB).

127 DM remission after Roux-en-Y gastric bypass (RYGB).

128 ten reported after Roux-en-Y gastric bypass (RYGB).

129 hernia (IH) after Roux-en-Y gastric bypass (RYGB).

130 weight loss after Roux-en-Y gastric bypass (RYGB).

131 omic profile after Roux-en-Y gastric bypass (RYGB).

132 es remission after Roux-en-Y gastric bypass (RYGB).

133 fect of bariatric (Roux-en-Y gastric bypass [RYGB]) surgery on insulin resistance.

134 lowing RYGB (RYGB + ET) or standard of care (RYGB).

135 Of 1033 eligible RYGB patients who consented to participate in longitudin

136 nd blood glucose and decreased with fasting, RYGB, and in postprandial states following VSG.

137 ding reduction in comorbid disease following RYGB.

138 nto individual patient experiences following RYGB.

139 ents in mental and physical health following RYGB, independent of weight loss, are unclear.

140 d 7.9%* at 12 months and 60 months following RYGB (*: P < 0.001).

141 ening for alcohol-related problems following RYGB is unclear.

142 sistance exercise training program following RYGB (RYGB + ET) or standard of care (RYGB).

143 ization) of self-reported symptoms following RYGB surgery.

144 p = 0.03 for SG; 31.2 to 232.9, p = 0.02 for RYGB) with no significant difference in the change in DI

145 on at 5 years was 21.3% for SG and 28.3% for RYGB (P < 0.0001).

146 ssation following surgery was comparable for RYGB and SG (RR 0.97, CI 0.90-1.04), with AGB having the

147 nd nonsurgical patients, and at 10 years for RYGB and nonsurgical patients.

148 tomy and the incremental increased-risk from RYGB has never been rigorously tested in this population

149 ery and exercise training (e.g., collagen I: RYGB -41% vs. RYGB + ET -76%; P <= 0.0001).

150 groups (+90% in controls, P < 0.01; +24% in RYGB, P = 0.10).

151 groups (+78% in controls, P < 0.01; +39% in RYGB, P = 0.01).

152 ndocrine responses were generally greater in RYGB patients than in controls.

153 y was associated with greater weight loss in RYGB, but not VSG.

154 glucose, lipid, and bile acid metabolism in RYGB-operated and unoperated individuals.

155 drate and 15/30 E% protein, respectively] in RYGB patients.

156 in stimulating enteroendocrine secretion in RYGB-operated and matched control individuals.

157 y beyond surgery alone (e.g., Matsuda index: RYGB 123% vs. RYGB + ET 325%; P <= 0.0001).

158 Laparoscopic RYGB results in highly favorable outcomes with reduced i

159 including 335 open RYGB and 316 laparoscopic RYGB.

160 expectedly higher in open (vs laparoscopic) RYGB (16.9% vs 4.7%; P = 0.02).

161 3.4%, P < 0.001).One-year post surgery, less RYGB-patients were lost-to follow-up (12.1% vs 16.5%, P

162 ients with VSG were less likely than matched RYGB patients to discontinue all diabetes medications (h

163 f preoperative antihypertensive medications (RYGB: OR, 0.104; 95% CI, 0.067-0.161 and AGB: OR, 0.239;

164 At baseline, more RYGB patients (median 40 years, 22% males) used a prescr

165 Over 90 days, 7.2% of RYGB and 6.2% of SG patients presented at least 1 compli

166 After 5 years, 3.7% of RYGB and 10.1% of SG patients had regained weight to wit

167 es should consider this potential benefit of RYGB when making informed decisions about obesity treatm

168 Among well-matched cohorts of RYGB and sleeve gastrectomy patients, incidence of prima

169 d and postprandial metabolic consequences of RYGB and VLCD in the same patients.

170 fects of RYGB and suggest that the effect of RYGB on the metabolite profile is mainly attributed to c

171 The effect of RYGB on type 2 diabetes drug treatment was evaluated in

172 m data have established the effectiveness of RYGB for weight loss and comorbidity amelioration.

173 ious findings of unique metabolic effects of RYGB and suggest that the effect of RYGB on the metaboli

174 bese pregnant women, women with a history of RYGB operation and a high risk of postprandial hypoglyca

175 women, as well as in women with a history of RYGB operation.

176 insight into preoperative identification of RYGB patients at higher risk for long-term suboptimal ou

177 the pragmatic use and short-term outcome of RYGB and SG in 3 countries in North-Western Europe.

178 mplete 10-year follow-up, including 335 open RYGB and 316 laparoscopic RYGB.

179 Patients undergoing open RYGB had a higher preoperative body mass index.

180 l adult health-plan members undergoing SG or RYGB for obesity in a multistate integrated health care

181 ormones, in patients who had undergone SG or RYGB vs controls.

182 morbidly obese patients randomized to SG or RYGB were included in a secondary outcome analysis.

183 Subjects undergoing SG or RYGB were studied with an intravenous glucose tolerance

184 ntify adults with diabetes undergoing VSG or RYGB in 2010 to 2016.

185 For single-stage procedures (809 pairs), RYGB was associated with longer LOS, and more complicati

186 In matched cohorts of patients, RYGB patients were more likely than patients with VSG to

187 Post-RYGB, 49 proteins were returned to normal levels after s

188 Post-RYGB, 835 women reported current drinking at 1 or more a

189 (45.1 +/- 3.6 years) pre- and 3 months post-RYGB, and euglycemic-hyperinsulinemic clamps were used t

190 en at risk for alcohol-related problems post-RYGB.

191 d a normalization of ribosomal proteins post-RYGB.

192 and 280 proteins differed significantly post-RYGB.

193 )) were demonstrated in the pre- versus post-RYGB, both P < 0.05.

194 dy mass index 31 +/- 6 kg/m2; 6 +/- 3 y post-RYGB) with recurrent postprandial hypoglycemia documente

195 ss index (BMI) 42.8 kg/m] undergoing primary RYGB between May 1, 2007 and June 30, 2012, were collect

196 ical Obesity Registry, who underwent primary RYGB between 2007 and 2012.

197 ith laparoscopic surgery for each procedure (RYGB 2.1% vs. 1.5%, P < 0.001; cholecystectomy 2.2% vs.

198 n increased risk of aSBO for each procedure [RYGB hazard ratio (HR) 1.24, P < 0.001; cholecystectomy

199 Patients receiving RYGB met international guidelines for having bariatric s

200 ce exercise training program following RYGB (RYGB + ET) or standard of care (RYGB).

201 rrent (single-stage) or interval (two-stage) RYGB or SG.

202 bjected to Roux-en-Y gastric bypass surgery (RYGB).

203 l decreases in medication use after surgery, RYGB patients had an 86% (32%, 140%) lower total diabete

204 itively-high perioperative risks surrounding RYGB.

205 Conversion to SG seems to be safer than RYGB.

206 h fewer reinterventions through 5 years than RYGB (hazard ratio, 0.78; 95% confidence interval, 0.74-

207 The findings confirm that RYGB does not indiscriminately lower body weight but spe

208 Despite evidence that RYGB alters alcohol pharmacokinetics and is associated w

209 The perception that RYGB has prohibitively-high perioperative risks among CK

210 Further, these findings suggest that RYGB may be particularly effective in patients with a pr

211 assigned participants, 35% and 31% from the RYGB group and 2% and 0% from the MT group achieved BP l

212 n BMI, 36.9 kg/m(2) [SD, 2.7]), 88% from the RYGB group and 80% from the MT group completed follow-up

213 outcome occurred in 73% of patients from the RYGB group compared with 11% of patients from the MT gro

214 quartile range) number of medications in the RYGB and MT groups at 3 years was 1 (0 to 2) and 3 (2.8

215 Total weight loss was 27.8% and -0.1% in the RYGB and MT groups, respectively.

216 drugs was two-fold higher at baseline in the RYGB cohort (22.8% vs 10.9%) and increased further after

217 In the RYGB cohort, large, sustained decreases occurred for tre

218 In the RYGB group only, individuals who showed lower taste-indu

219 It was only in the RYGB group that betatrophin was negatively related to th

220 In the RYGB group, 13 patients developed hypovitaminosis B(12)

221 d by significant hypoglycaemic events in the RYGB group.

222 mprovement in GERD symptoms when compared to RYGB (30.4% vs 30.8%, p = 0.7015).

223 of worsening GERD symptoms when compared to RYGB, the majority of patients (>80%) in this study expe

224 rcent of all patients required conversion to RYGB for severe reflux.

225 AGB patients often present for conversion to RYGB or SG.

226 The intestine adapts differently to RYGB vs VSG.

227 ry, sleeve gastrectomy is often preferred to RYGB based on perceptions of prohibitively-high perioper

228 Prior to RYGB, 12 of 26 patients had mild to moderate steatorrhea

229 of SG has increased dramatically relative to RYGB for the treatment of obesity.

230 to alter the systemic metabolic response to RYGB.

231 bolism following VLCD but not in response to RYGB.

232 mpacted the global metabolomics responses to RYGB, and patients who underwent the gallbladder removal

233 effects were seen in male mice subjected to RYGB at 5-6 weeks, although growth was slightly inhibite

234 and body mass index but who did not undergo RYGB surgery were surveyed as a point of reference.

235 All patients (N = 1087) undergoing RYGB at a single institution over a 20-year study period

236 Adults undergoing RYGB in a US multi-center cohort study wore an activity

237 Adults undergoing RYGB surgery entered a prospective cohort study between

238 Patients with NASH undergoing RYGB are more susceptible to early transient deteriorati

239 Only 19 of 564 patients undergoing RYGB (3.4%) regained weight back to within an estimated

240 A total of 405 of 564 patients undergoing RYGB (71.8%) had more than 20% estimated weight loss, an

241 Patients undergoing RYGB and nonsurgical matches had a mean body mass index

242 Results: The 1787 patients undergoing RYGB had a mean (SD) age of 52.1 (8.5) years and 5305 no

243 hort study included 9908 patients undergoing RYGB in Denmark during 2006 to 2010 and 99,080 matched g

244 Patients undergoing RYGB lost 16.9% (95% CI, 6.2%-27.6%) more of their basel

245 Patients undergoing RYGB lost 21% (95% CI, 11%-31%) more of their baseline w

246 At 4 years, patients undergoing RYGB lost 27.5% (95% CI, 23.8%-31.2%) of their baseline

247 One in 10 patients undergoing RYGB surgery developed chronic abdominal pain requiring

248 Of 2238 patients undergoing RYGB surgery, 1429 (63.7%) responded to the survey.

249 ric patients with diabetes, those undergoing RYGB were more likely to come off all medications than t

250 ears were compared among veterans undergoing RYGB (n = 1785), SG (n = 379), and AGB (n = 246).

251 e gastrectomy, 12 patients who had undergone RYGB, and 12 individuals who had undergone neither surge

252 (83%) underwent SG and 1,771 (17%) underwent RYGB.

253 y mass index [BMI] was 45.9; 70.4% underwent RYGB; 25.0% underwent LAGB).

254 hundred sixty-seven matched pairs underwent RYGB; single-stage patients experienced shorter length o

255 Obese male rats underwent RYGB, VSG, or sham (control) operations.

256 etween individuals or animals that underwent RYGB vs VSG.

257 In rats and humans that underwent RYGB, the Roux limb became hyperplasic, with an increase

258 lial cells of rats and humans that underwent RYGB.

259 ux limb sections from patients who underwent RYGB 1-5 years after surgery.

260 otal of 659 patients with T2DM who underwent RYGB and SG at an academic center in the United States a

261 Of 807 participants who underwent RYGB and were given an activity monitor, 649 (80%) had s

262 glucose occurs in obese people who underwent RYGB compared with those who underwent laparoscopic adju

263 ctive cohorts of 1787 veterans who underwent RYGB from January 1, 2000, through September 30, 2011 (5

264 1423 participants of the 1770 who underwent RYGB had data on satisfaction with surgery (81% female;

265 with body mass index >=35 kg/m who underwent RYGB or SG procedures from January 2005 through Septembe

266 CKD patients who underwent RYGB or sleeve gastrectomy between 2015 and 2017 were id

267 with inclusion of all patients who underwent RYGB surgery between 2010 and 2015.

268 31, 2014, among 2238 patients who underwent RYGB surgery between January 1, 2006, and December 31, 2

269 derwent SG and 19,954 patients who underwent RYGB with a follow-up of 79.2%.

270 year weight change in veterans who underwent RYGB, adjustable gastric banding (AGB), or sleeve gastre

271 Among adults who underwent RYGB, multiple objective PA measures were associated wit

272 this retrospective cohort study followed up RYGB patients before surgery to 7 to 12 years after surg

273 0.140-0.408), and preoperative diuretic use (RYGB: OR, 1.729; 95% CI, 1.462-2.045 and AGB: OR, 1.648;

274 CI, 1.039-1.351), preoperative insulin use (RYGB: OR, 0.14; 95% CI, 0.114-0.171; AGB: OR, 0.174; 95%

275 566), and other antidiabetic medication use (RYGB: OR, 0.747; 95% CI, 0.568-0.981 and AGB: OR, 0.506;

276 0.131-0.230), preoperative sulfonylurea use (RYGB: OR, 0.616; 95% CI, 0.505-0.752 and AGB: OR, 0.449;

277 urgical reinterventions when examined versus RYGB.

278 ry alone (e.g., Matsuda index: RYGB 123% vs. RYGB + ET 325%; P <= 0.0001).

279 se training (e.g., collagen I: RYGB -41% vs. RYGB + ET -76%; P <= 0.0001).

280 ase in fasting acylcarnitine levels, whereas RYGB, both immediately and after a recovery period, resu

281 was an intermediate group, however, in which RYGB was significantly more effective than SG, likely re

282 With RYGB, there was a trend toward increased BA [total: 1.37

283 cal and/or metabolic changes associated with RYGB may more effectively "reset" the neural processing

284 Most changes previously associated with RYGB were found to be consequences of the presurgical di

285 f ghrelin were lower after SG, compared with RYGB and controls.

286 in all categories studied when compared with RYGB at 5-year follow-up.

287 , long-term risks following SG compared with RYGB have not been adequately defined in a large populat

288 ong-term safety profile of LSG compared with RYGB should be an essential part of the discussion in pa

289 y weight and composition of female mice with RYGB performed at 6 weeks of age were not significantly

290 Of 307 participants operated with RYGB, 233 (76%) completed the study questionnaires.

291 nal study of 38 obese diabetic patients with RYGB, we found higher baseline stearic acid/palmitic aci

292 Both procedures were safe, with RYGB having higher weight loss and follow-up rates at th

293 It is unclear how satisfaction with RYGB surgery changes over time following surgery and fac

294 Level of satisfaction with RYGB surgery significantly decreased 3-7 years following

295 of participants who were not satisfied with RYGB surgery significantly increased from 15.4% 3 years

296 In the cohort of pregnant women with RYGB and exaggerated risk of postprandial hypoglycaemic

297 0.982; 95% CI, 0.971-0.933), procedure year (RYGB: OR, 1.11; 95% CI, 1.012-1.218 and AGB: OR, 1.185;

298 At 1 year, RYGB patients had 28.4%TWL (95% confidence interval: 28.

299 At 10 years, RYGB patients had 20.2%TWL (19.3, 21.0) and nonsurgical

300 At 5 years, RYGB had 21.7%TWL (21.5, 22.0), SG 16.0%TWL (15.4, 16.6)